SCYNEXIS Inc. Appoints Dr. Steven K. Burke to Board

What Happened

• SCYNEXIS announced on Sept. 18, 2026 that it appointed Steven K. Burke, M.D., to its Board of Directors and named him to the Nominating and Corporate Governance Committee. His term runs until the company’s 2027 Annual Meeting of Stockholders and until a successor is elected. The company filed a press release about the appointment on Sept. 22, 2026 (Exhibit 99.1).

Key Details

• Appointment date and term: effective Sept. 18, 2026; serves until the 2027 Annual Meeting.
• Committee role: member of the Nominating and Corporate Governance Committee.
• Cash compensation: annual retainer of $45,000 plus $5,000 annual retainer for committee service; non-employee directors may elect stock options in lieu of cash.
• Equity grants: initial stock option to purchase 5,750 shares (exercise price $4.46, the Sept. 18, 2026 closing price) and 5,750 restricted stock units (RSUs); initial options vest one-third after 1 year, remainder monthly over the next 24 months; initial RSUs vest one-third each year. Annual equity grant consists of options for 2,875 shares and 2,875 RSUs vesting in full after one year.

Why It Matters

• Governance: a new independent director and addition to the Nominating & Corporate Governance Committee may influence board oversight and director selection processes.
• Shareholder impact: compensation includes stock options and RSUs, which align the director’s incentives with shareholders but will create future equity issuance (dilution) when vested awards are exercised or settled.
• Disclosure: the company reported no related-party arrangements or transactions requiring additional disclosure under Item 404(a), and it has entered into its standard indemnification agreement with Dr. Burke.